New CAR T-Cell therapy targets Hard-to-Treat myeloma
NCT ID NCT07611149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to check for side effects, while also seeing if the treatment shrinks the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UF-KURE-BCMA CAR T-cells
- What this could lead to
- If successful, this could point toward a new treatment option for advanced multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12 people, focused on safety. The treatment may not work or could cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on incurable blood cancer
- Engineered immune cells take on Hard-to-Treat myeloma